Login Register Cart 0
Generic placeholder image

Current Computer-Aided Drug Design

Editor-in-Chief

ISSN (Print): 1573-4099
ISSN (Online): 1875-6697

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

Author(s): Juying Chen*, Xiaozhe Wu, Hongzhe Wang, Xiaoshan Lian, Bing Li and Xiangbo Zhan

Volume 20, Issue 6, 2024

Published on: 20 September, 2023

Page: [736 - 751] Pages: 16

DOI: 10.2174/1573409920666230907093331

Price: $65

Abstract

Aims: This study aims to evaluate the efficacy and safety of PARP inhibitor therapy in advanced ovarian cancer and identify the optimal treatment for the survival of patients.

Background: The diversity of PARP inhibitors makes clinicians confused about the optimal strategy and the most effective BRCAm mutation-based regimen for the survival of patients with advanced ovarian cancer.

Objectives: The objective of this study is to compare the effects of various PARP inhibitors alone or in combination with other agents in advanced ovarian cancer.

Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for relevant studies on PARP inhibitors for ovarian cancer. Bayesian network meta-analysis was performed using Stata 15.0 and R 4.0.4. The primary outcome was the overall PFS, and the secondary outcomes included OS, AE3, DISAE, and TFST.

Results: Fifteen studies involving 5,788 participants were included. The Bayesian network metaanalysis results showed that olaparibANDAI was the most beneficial in prolonging overall PFS and non-BRCAm PFS, followed by niraparibANDAI. However, for BRCAm patients, olaparibTR might be the most effective, followed by niraparibANDAI. Olaparib was the most effective for the OS of BRCAm patients. AI, olaparibANDAI, and veliparibTR were more likely to induce grade 3 or higher adverse events. AI and olaparibANDAI were more likely to cause DISAE.

Conclusion: PARP inhibitors are beneficial to the survival of patients with advanced ovarian cancer. The olaparibTR is the most effective for BRCAm patients, whereas olaparibANDAI and niraparibANDAI are preferable for non-BRCAm patients.

Other: More high-quality studies are desired to investigate the efficacy and safety of PARP inhibitors in patients with other genetic performances.

Keywords: PARP inhibitors, olaparib, rucaparib, niraparib, veliparib, ovarian cancer.

« Previous Next »
Graphical Abstract

[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Torre, L.A.; Trabert, B.; DeSantis, C.E.; Miller, K.D.; Samimi, G.; Runowicz, C.D.; Gaudet, M.M.; Jemal, A.; Siegel, R.L. Ovarian cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(4), 284-296.
[http://dx.doi.org/10.3322/caac.21456] [PMID: 29809280]
[3]
Ledermann, J.A.; Raja, F.A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2013, 24(6), vi24-vi32.
[http://dx.doi.org/10.1093/annonc/mdt333] [PMID: 24078660]
[4]
Oncology, C.S.G. Clinical guidelines of PARP inhibitors in ovarian cancer. Elect. J. Integr. Can. The., 2022, 8(3), 64-77.
[5]
Ashworth, A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol., 2008, 26(22), 3785-3790.
[http://dx.doi.org/10.1200/JCO.2008.16.0812] [PMID: 18591545]
[6]
Ohmoto, A.; Yachida, S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets Ther., 2017, 10, 5195-5208.
[http://dx.doi.org/10.2147/OTT.S139336] [PMID: 29138572]
[7]
Chang, H.H.Y.; Pannunzio, N.R.; Adachi, N.; Lieber, M.R. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat. Rev. Mol. Cell Biol., 2017, 18(8), 495-506.
[http://dx.doi.org/10.1038/nrm.2017.48] [PMID: 28512351]
[8]
Kieffer, S.R.; Lowndes, N.F. Immediate-early, early, and late responses to dna double stranded breaks. Front. Genet., 2022, 13, 793884.
[http://dx.doi.org/10.3389/fgene.2022.793884] [PMID: 35173769]
[9]
Yang, G.; Chen, Y.; Wu, J.; Chen, S.H.; Liu, X.; Singh, A.K.; Yu, X. Poly(ADP-ribosyl)ation mediates early phase histone eviction at DNA lesions. Nucleic Acids Res., 2020, 48(6), 3001-3013.
[http://dx.doi.org/10.1093/nar/gkaa022] [PMID: 31965183]
[10]
Yang, G.; Liu, C.; Chen, S.H.; Kassab, M.A.; Hoff, J.D.; Walter, N.G.; Yu, X. Super-resolution imaging identifies PARP1 and the Ku complex acting as DNA double-strand break sensors. Nucleic Acids Res., 2018, 46(7), 3446-3457.
[http://dx.doi.org/10.1093/nar/gky088] [PMID: 29447383]
[11]
Cheng, Q.; Barboule, N.; Frit, P.; Gomez, D.; Bombarde, O.; Couderc, B.; Ren, G.S.; Salles, B.; Calsou, P. Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. Nucleic Acids Res., 2011, 39(22), 9605-9619.
[http://dx.doi.org/10.1093/nar/gkr656] [PMID: 21880593]
[12]
Mao, P.; Liu, J.; Zhang, Z.; Zhang, H.; Liu, H.; Gao, S.; Rong, Y.S.; Zhao, Y. Homologous recombination-dependent repair of telomeric DSBs in proliferating human cells. Nat. Commun., 2016, 7(1), 12154.
[http://dx.doi.org/10.1038/ncomms12154] [PMID: 27396625]
[13]
Konstantinopoulos, P.A.; Matulonis, U.A. PARP inhibitors in ovarian cancer: A trailblazing and transformative journey. Clin. Cancer Res., 2018, 24(17), 4062-4065.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-1314] [PMID: 29871906]
[14]
Gao, Q.; Zhu, J.; Zhao, W.; Huang, Y.; An, R.; Zheng, H.; Qu, P.; Wang, L.; Zhou, Q.; Wang, D.; Lou, G.; Wang, J.; Wang, K.; Low, J.; Kong, B.; Rozita, A.M.; Sen, L.C.; Yin, R.; Xie, X.; Liu, J.; Sun, W.; Su, J.; Zhang, C.; Zang, R.; Ma, D. Olaparib maintenance monotherapy in asian patients with platinum-sensitive relapsed ovarian cancer: Phase III Trial (L-MOCA). Clin. Cancer Res., 2022, 28(11), 2278-2285.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-3023] [PMID: 35131903]
[15]
Vanderstichele, A.; Loverix, L.; Busschaert, P.; Van Nieuwenhuysen, E.; Han, S.N.; Concin, N.; Callewaert, T.; Olbrecht, S.; Salihi, R.; Berteloot, P.; Neven, P.; Lambrechts, D.; Van Gorp, T.; Vergote, I. Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician’s choice chemotherapy in relapsed ovarian cancer. Gynecol. Oncol., 2022, 165(1), 14-22.
[http://dx.doi.org/10.1016/j.ygyno.2022.01.034] [PMID: 35177277]
[16]
Poveda, A.; Lheureux, S.; Colombo, N.; Cibula, D.; Lindemann, K.; Weberpals, J.; Bjurberg, M.; Oaknin, A.; Sikorska, M.; González-Martín, A.; Madry, R.; Pérez, M.J.R.; Ledermann, J.; Davidson, R.; Blakeley, C.; Bennett, J.; Barnicle, A.; Škof, E. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecol. Oncol., 2022, 164(3), 498-504.
[http://dx.doi.org/10.1016/j.ygyno.2021.12.025] [PMID: 35063276]
[17]
Banerjee, S.; Moore, K.N.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.H.; Holmes, E.; Lowe, E.S.; DiSilvestro, P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2021, 22(12), 1721-1731.
[http://dx.doi.org/10.1016/S1470-2045(21)00531-3] [PMID: 34715071]
[18]
Mirza, M.R.; Åvall Lundqvist, E.; Birrer, M.J.; dePont Christensen, R.; Nyvang, G.B.; Malander, S.; Anttila, M.; Werner, T.L.; Lund, B.; Lindahl, G.; Hietanen, S.; Peen, U.; Dimoula, M.; Roed, H.; Ør Knudsen, A.; Staff, S.; Krog Vistisen, A.; Bjørge, L.; Mäenpää, J.U. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): A randomised, phase 2, superiority trial. Lancet Oncol., 2019, 20(10), 1409-1419.
[http://dx.doi.org/10.1016/S1470-2045(19)30515-7] [PMID: 31474354]
[19]
Coleman, R.L.; Fleming, G.F.; Brady, M.F.; Swisher, E.M.; Steffensen, K.D.; Friedlander, M.; Okamoto, A.; Moore, K.N.; Efrat Ben-Baruch, N.; Werner, T.L.; Cloven, N.G.; Oaknin, A.; DiSilvestro, P.A.; Morgan, M.A.; Nam, J.H.; Leath, C.A., III; Nicum, S.; Hagemann, A.R.; Littell, R.D.; Cella, D.; Baron-Hay, S.; Garcia-Donas, J.; Mizuno, M.; Bell-McGuinn, K.; Sullivan, D.M.; Bach, B.A.; Bhattacharya, S.; Ratajczak, C.K.; Ansell, P.J.; Dinh, M.H.; Aghajanian, C.; Bookman, M.A. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2403-2415.
[http://dx.doi.org/10.1056/NEJMoa1909707] [PMID: 31562800]
[20]
Ray-Coquard, I.; Pautier, P.; Pignata, S.; Pérol, D.; González-Martín, A.; Berger, R.; Fujiwara, K.; Vergote, I.; Colombo, N.; Mäenpää, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Guerra Alía, E.M.; Reinthaller, A.; Nagao, S.; Lefeuvre-Plesse, C.; Canzler, U.; Scambia, G.; Lortholary, A.; Marmé, F.; Combe, P.; de Gregorio, N.; Rodrigues, M.; Buderath, P.; Dubot, C.; Burges, A.; You, B.; Pujade-Lauraine, E.; Harter, P. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2416-2428.
[http://dx.doi.org/10.1056/NEJMoa1911361] [PMID: 31851799]
[21]
Hutton, B.; Salanti, G.; Caldwell, D.M.; Chaimani, A.; Schmid, C.H.; Cameron, C.; Ioannidis, J.P.A.; Straus, S.; Thorlund, K.; Jansen, J.P.; Mulrow, C.; Catalá-López, F.; Gøtzsche, P.C.; Dickersin, K.; Boutron, I.; Altman, D.G.; Moher, D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med., 2015, 162(11), 777-784.
[http://dx.doi.org/10.7326/M14-2385] [PMID: 26030634]
[22]
Lin, L. Comparison of four heterogeneity measures for meta‐analysis. J. Eval. Clin. Pract., 2020, 26(1), 376-384.
[http://dx.doi.org/10.1111/jep.13159] [PMID: 31234230]
[23]
Riley, R.D.; Higgins, J.P.T.; Deeks, J.J. Interpretation of random effects meta-analyses. BMJ, 2011, 342(feb10 2), d549.
[http://dx.doi.org/10.1136/bmj.d549] [PMID: 21310794]
[24]
Kaye, S.B.; Lubinski, J.; Matulonis, U.; Ang, J.E.; Gourley, C.; Karlan, B.Y.; Amnon, A.; Bell-McGuinn, K.M.; Chen, L.M.; Friedlander, M.; Safra, T.; Vergote, I.; Wickens, M.; Lowe, E.S.; Carmichael, J.; Kaufman, B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol., 2012, 30(4), 372-379.
[http://dx.doi.org/10.1200/JCO.2011.36.9215] [PMID: 22203755]
[25]
Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Macpherson, E.; Watkins, C.; Carmichael, J.; Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med., 2012, 366(15), 1382-1392.
[http://dx.doi.org/10.1056/NEJMoa1105535] [PMID: 22452356]
[26]
Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.L.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Fielding, A.; Spencer, S.; Dougherty, B.; Orr, M.; Hodgson, D.; Barrett, J.C.; Matulonis, U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol., 2014, 15(8), 852-861.
[http://dx.doi.org/10.1016/S1470-2045(14)70228-1] [PMID: 24882434]
[27]
Liu, J.F.; Barry, W.T.; Birrer, M.; Lee, J.M.; Buckanovich, R.J.; Fleming, G.F.; Rimel, B.J.; Buss, M.K.; Nattam, S.; Hurteau, J.; Luo, W.; Quy, P.; Whalen, C.; Obermayer, L.; Lee, H.; Winer, E.P.; Kohn, E.C.; Ivy, S.P.; Matulonis, U.A. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol., 2014, 15(11), 1207-1214.
[http://dx.doi.org/10.1016/S1470-2045(14)70391-2] [PMID: 25218906]
[28]
Oza, A.M.; Cibula, D.; Benzaquen, A.O.; Poole, C.; Mathijssen, R.H.J.; Sonke, G.S.; Colombo, N.; Špaček, J.; Vuylsteke, P.; Hirte, H.; Mahner, S.; Plante, M.; Schmalfeldt, B.; Mackay, H.; Rowbottom, J.; Lowe, E.S.; Dougherty, B.; Barrett, J.C.; Friedlander, M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol., 2015, 16(1), 87-97.
[http://dx.doi.org/10.1016/S1470-2045(14)71135-0] [PMID: 25481791]
[29]
Ledermann, J.A.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Fielding, A.; Spencer, S.; Rowe, P.; Lowe, E.; Hodgson, D.; Sovak, M.A.; Matulonis, U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol., 2016, 17(11), 1579-1589.
[http://dx.doi.org/10.1016/S1470-2045(16)30376-X] [PMID: 27617661]
[30]
Mirza, M.R.; Monk, B.J.; Herrstedt, J.; Oza, A.M.; Mahner, S.; Redondo, A.; Fabbro, M.; Ledermann, J.A.; Lorusso, D.; Vergote, I.; Ben-Baruch, N.E.; Marth, C.; Mądry, R.; Christensen, R.D.; Berek, J.S.; Dørum, A.; Tinker, A.V.; du Bois, A.; González-Martín, A.; Follana, P.; Benigno, B.; Rosenberg, P.; Gilbert, L.; Rimel, B.J.; Buscema, J.; Balser, J.P.; Agarwal, S.; Matulonis, U.A. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med., 2016, 375(22), 2154-2164.
[http://dx.doi.org/10.1056/NEJMoa1611310] [PMID: 27717299]
[31]
Coleman, R.L.; Oza, A.M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.I.; Clamp, A.; Scambia, G.; Leary, A.; Holloway, R.W.; Gancedo, M.A.; Fong, P.C.; Goh, J.C.; O’Malley, D.M.; Armstrong, D.K.; Garcia-Donas, J.; Swisher, E.M.; Floquet, A.; Konecny, G.E.; McNeish, I.A.; Scott, C.L.; Cameron, T.; Maloney, L.; Isaacson, J.; Goble, S.; Grace, C.; Harding, T.C.; Raponi, M.; Sun, J.; Lin, K.K.; Giordano, H.; Ledermann, J.A.; Buck, M.; Dean, A.; Friedlander, M.L.; Goh, J.C.; Harnett, P.; Kichenadasse, G.; Scott, C.L.; Denys, H.; Dirix, L.; Vergote, I.; Elit, L.; Ghatage, P.; Oza, A.M.; Plante, M.; Provencher, D.; Weberpals, J.I.; Welch, S.; Floquet, A.; Gladieff, L.; Joly, F.; Leary, A.; Lortholary, A.; Lotz, J.; Medioni, J.; Tredan, O.; You, B.; El-Balat, A.; Hänle, C.; Krabisch, P.; Neunhöffer, T.; Pölcher, M.; Wimberger, P.; Amit, A.; Kovel, S.; Leviov, M.; Safra, T.; Shapira-Frommer, R.; Stemmer, S.; Bologna, A.; Colombo, N.; Lorusso, D.; Pignata, S.; Sabbatini, R.F.; Scambia, G.; Tamberi, S.; Zamagni, C.; Fong, P.C.; O’Donnell, A.; Gancedo, M.A.; Herraez, A.C.; Garcia-Donas, J.; Guerra, E.M.; Oaknin, A.; Palacio, I.; Romero, I.; Sanchez, A.; Banerjee, S.N.; Clamp, A.; Drew, Y.; Gabra, H.G.; Jackson, D.; Ledermann, J.A.; McNeish, I.A.; Parkinson, C.; Powell, M.; Aghajanian, C.; Armstrong, D.K.; Birrer, M.J.; Buss, M.K.; Chambers, S.K.; Chen, L.; Coleman, R.L.; Holloway, R.W.; Konecny, G.E.; Ma, L.; Morgan, M.A.; Morris, R.T.; Mutch, D.G.; O’Malley, D.M.; Slomovitz, B.M.; Swisher, E.M.; Vanderkwaak, T.; Vulfovich, M. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 390(10106), 1949-1961.
[http://dx.doi.org/10.1016/S0140-6736(17)32440-6] [PMID: 28916367]
[32]
Pujade-Lauraine, E.; Ledermann, J.A.; Selle, F.; Gebski, V.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Poveda, A.; Pignata, S.; Friedlander, M.; Colombo, N.; Harter, P.; Fujiwara, K.; Ray-Coquard, I.; Banerjee, S.; Liu, J.; Lowe, E.S.; Bloomfield, R.; Pautier, P.; Korach, J.; Huzarski, T.; Byrski, T.; Pautier, P.; Friedlander, M.; Harter, P.; Colombo, N.; Pignata, S.; Scambia, G.; Nicoletto, M.; Nussey, F.; Clamp, A.; Penson, R.; Oza, A.; Poveda Velasco, A.; Rodrigues, M.; Lotz, J-P.; Selle, F.; Ray-Coquard, I.; Provencher, D.; Prat Aparicio, A.; Vidal Boixader, L.; Scott, C.; Tamura, K.; Yunokawa, M.; Lisyanskaya, A.; Medioni, J.; Pécuchet, N.; Dubot, C.; de la Motte Rouge, T.; Kaminsky, M-C.; Weber, B.; Lortholary, A.; Parkinson, C.; Ledermann, J.; Williams, S.; Banerjee, S.; Cosin, J.; Hoffman, J.; Penson, R.; Plante, M.; Covens, A.; Sonke, G.; Joly, F.; Floquet, A.; Banerjee, S.; Hirte, H.; Amit, A.; Park-Simon, T-W.; Matsumoto, K.; Tjulandin, S.; Kim, J.H.; Gladieff, L.; Sabbatini, R.; O’Malley, D.; Timmins, P.; Kredentser, D.; Laínez Milagro, N.; Barretina Ginesta, M.P.; Tibau Martorell, A.; Gómez de Liaño Lista, A.; Ojeda González, B.; Mileshkin, L.; Mandai, M.; Boere, I.; Ottevanger, P.; Nam, J-H.; Filho, E.; Hamizi, S.; Cognetti, F.; Warshal, D.; Dickson-Michelson, E.; Kamelle, S.; McKenzie, N.; Rodriguez, G.; Armstrong, D.; Chalas, E.; Celano, P.; Behbakht, K.; Davidson, S.; Welch, S.; Helpman, L.; Fishman, A.; Bruchim, I.; Sikorska, M.; Słowińska, A.; Rogowski, W.; Bidziński, M.; Śpiewankiewicz, B.; Casado Herraez, A.; Mendiola Fernández, C.; Gropp-Meier, M.; Saito, T.; Takehara, K.; Enomoto, T.; Watari, H.; Choi, C.H.; Kim, B-G.; Kim, J.W.; Hegg, R.; Vergote, I. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2017, 18(9), 1274-1284.
[http://dx.doi.org/10.1016/S1470-2045(17)30469-2] [PMID: 28754483]
[33]
Moore, K.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; Gourley, C.; Banerjee, S.; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.; Mathews, C.; Liu, J.; Lowe, E.S.; Bloomfield, R.; DiSilvestro, P. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med., 2018, 379(26), 2495-2505.
[http://dx.doi.org/10.1056/NEJMoa1810858] [PMID: 30345884]
[34]
González-Martín, A.; Pothuri, B.; Vergote, I.; DePont Christensen, R.; Graybill, W.; Mirza, M.R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; Baumann, K.; Jardon, K.; Redondo, A.; Moore, R.G.; Vulsteke, C.; O’Cearbhaill, R.E.; Lund, B.; Backes, F.; Barretina-Ginesta, P.; Haggerty, A.F.; Rubio-Pérez, M.J.; Shahin, M.S.; Mangili, G.; Bradley, W.H.; Bruchim, I.; Sun, K.; Malinowska, I.A.; Li, Y.; Gupta, D.; Monk, B.J. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med., 2019, 381(25), 2391-2402.
[http://dx.doi.org/10.1056/NEJMoa1910962] [PMID: 31562799]
[35]
Liu, J.F.; Barry, W.T.; Birrer, M.; Lee, J.M.; Buckanovich, R.J.; Fleming, G.F.; Rimel, B.J.; Buss, M.K.; Nattam, S.R.; Hurteau, J.; Luo, W.; Curtis, J.; Whalen, C.; Kohn, E.C.; Ivy, S.P.; Matulonis, U.A. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann. Oncol., 2019, 30(4), 551-557.
[http://dx.doi.org/10.1093/annonc/mdz018] [PMID: 30753272]
[36]
Ledermann, J.A.; Oza, A.M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.I.; Clamp, A.R.; Scambia, G.; Leary, A.; Holloway, R.W.; Gancedo, M.A.; Fong, P.C.; Goh, J.C.; O’Malley, D.M.; Armstrong, D.K.; Banerjee, S.; García-Donas, J.; Swisher, E.M.; Cameron, T.; Maloney, L.; Goble, S.; Coleman, R.L. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): Post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2020, 21(5), 710-722.
[http://dx.doi.org/10.1016/S1470-2045(20)30061-9] [PMID: 32359490]
[37]
Penson, R.T.; Valencia, R.V.; Cibula, D.; Colombo, N.; Leath, C.A., III; Bidziński, M.; Kim, J.W.; Nam, J.H.; Madry, R.; Hernández, C.; Mora, P.A.R.; Ryu, S.Y.; Milenkova, T.; Lowe, E.S.; Barker, L.; Scambia, G. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline brca1/2 mutation (SOLO3): A randomized phase iii trial. J. Clin. Oncol., 2020, 38(11), 1164-1174.
[http://dx.doi.org/10.1200/JCO.19.02745] [PMID: 32073956]
[38]
Swisher, E.M.; Aghajanian, C.; O’Malley, D.M.; Fleming, G.F.; Kaufmann, S.H.; Levine, D.A.; Birrer, M.J.; Moore, K.N.; Spirtos, N.M.; Shahin, M.S.; Reid, T.J.; Friedlander, M.; Steffensen, K.D.; Okamoto, A.; Sehgal, V.; Ansell, P.J.; Dinh, M.H.; Bookman, M.A.; Coleman, R.L. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol. Oncol., 2022, 164(2), 245-253.
[http://dx.doi.org/10.1016/j.ygyno.2021.12.003] [PMID: 34906376]
[39]
Wu, L.; Zhu, J.; Yin, R.; Wu, X.; Lou, G.; Wang, J.; Gao, Y.; Kong, B.; Lu, X.; Zhou, Q.; Wang, Y.; Chen, Y.; Lu, W.; Li, W.; Cheng, Y.; Liu, J.; Ma, X.; Zhang, J. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol. Oncol., 2021, 160(1), 175-181.
[http://dx.doi.org/10.1016/j.ygyno.2020.10.005] [PMID: 33250205]
[40]
Poveda, A.; Floquet, A.; Ledermann, J.A.; Asher, R.; Penson, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Pignata, S.; Friedlander, M.; Baldoni, A.; Park-Simon, T.W.; Tamura, K.; Sonke, G.S.; Lisyanskaya, A.; Kim, J.H.; Filho, E.A.; Milenkova, T.; Lowe, E.S.; Rowe, P.; Vergote, I.; Pujade-Lauraine, E.; Korach, J.; Huzarski, T.; Byrski, T.; Pautier, P.; Friedlander, M.; Harter, P.; Colombo, N.; Pignata, S.; Scambia, G.; Nicoletto, M.; Nussey, F.; Clamp, A.; Penson, R.; Oza, A.; Poveda Velasco, A.; Rodrigues, M.; Lotz, J-P.; Selle, F.; Ray-Coquard, I.; Provencher, D.; Prat Aparicio, A.; Vidal Boixader, L.; Scott, C.; Tamura, K.; Yunokawa, M.; Lisyanskaya, A.; Medioni, J.; Pécuchet, N.; Dubot, C.; De La Motte Rouge, T.; Kaminsky, M-C.; Weber, B.; Lortholary, A.; Parkinson, C.; Ledermann, J.; Williams, S.; Banerjee, S.; Cosin, J.; Hoffman, J.; Penson, R.; Plante, M.; Covens, A.; Sonke, G.; Joly, F.; Floquet, A.; Banerjee, S.; Hirte, H.; Amit, A.; Park-Simon, T-W.; Matsumoto, K.; Tjulandin, S.; Hoon Kim, J.; Gladieff, L.; Sabbatini, R.; O’Malley, D.; Timmins, P.; Kredentser, D.; Laínez Milagro, N.; Barretina Ginesta, M.P.; Tibau Martorell, A.; Gómez De Liaño Lista, A.; Ojeda González, B.; Mileshkin, L.; Mandai, M.; Boere, I.; Ottevanger, P.; Nam, J-H.; Filho, E.; Hamizi, S.; Cognetti, F.; Warshal, D.; Dickson-Michelson, E.; Kamelle, S.; McKenzie, N.; Rodriguez, G.; Armstrong, D.; Chalas, E.; Celano, P.; Behbakht, K.; Davidson, S.; Welch, S.; Helpman, L.; Fishman, A.; Bruchim, I.; Sikorska, M.; Słowińska, A.; Rogowski, W.; Bidziński, M.; Śpiewankiewicz, B.; Casado Herraez, A.; Mendiola Fernández, C.; Gropp-Meier, M.; Saito, T.; Takehara, K.; Enomoto, T.; Watari, H.; Choi, C.H.; Kim, B-G.; Weon Kim, J.; Hegg, R.; Vergote, I. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2021, 22(5), 620-631.
[http://dx.doi.org/10.1016/S1470-2045(21)00073-5] [PMID: 33743851]
[41]
Wu, X.H.; Zhu, J.Q.; Yin, R.T.; Yang, J.X.; Liu, J.H.; Wang, J.; Wu, L.Y.; Liu, Z.L.; Gao, Y.N.; Wang, D.B.; Lou, G.; Yang, H.Y.; Zhou, Q.; Kong, B.H.; Huang, Y.; Chen, L.P.; Li, G.L.; An, R.F.; Wang, K.; Zhang, Y.; Yan, X.J.; Lu, X.; Lu, W.G.; Hao, M.; Wang, L.; Cui, H.; Chen, Q.H.; Abulizi, G.; Huang, X.H.; Tian, X.F.; Wen, H.; Zhang, C.; Hou, J.M.; Mirza, M.R. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): A randomized, double-blind, placebo-controlled phase III trial☆. Ann. Oncol., 2021, 32(4), 512-521.
[http://dx.doi.org/10.1016/j.annonc.2020.12.018] [PMID: 33453391]
[42]
Chan, N.; Bristow, R.G. “Contextual” synthetic lethality and/or loss of heterozygosity: Tumor hypoxia and modification of DNA repair. Clin. Cancer Res., 2010, 16(18), 4553-4560.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-0527] [PMID: 20823145]
[43]
Hegan, D.C.; Lu, Y.; Stachelek, G.C.; Crosby, M.E.; Bindra, R.S.; Glazer, P.M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl. Acad. Sci., 2010, 107(5), 2201-2206.
[http://dx.doi.org/10.1073/pnas.0904783107] [PMID: 20133863]
[44]
Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; Bois, A.; Sehouli, J.; Kimmig, R.; Stähle, A.; Collinson, F.; Essapen, S.; Gourley, C.; Lortholary, A.; Selle, F.; Mirza, M.R.; Leminen, A.; Plante, M.; Stark, D.; Qian, W.; Parmar, M.K.B.; Oza, A.M. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med., 2011, 365(26), 2484-2496.
[http://dx.doi.org/10.1056/NEJMoa1103799] [PMID: 22204725]
[45]
Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; Boente, M.; Birrer, M.J.; Liang, S.X. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med., 2011, 365(26), 2473-2483.
[http://dx.doi.org/10.1056/NEJMoa1104390] [PMID: 22204724]
[46]
Norquist, B.M.; Brady, M.F.; Harrell, M.I.; Walsh, T.; Lee, M.K.; Gulsuner, S.; Bernards, S.S.; Casadei, S.; Burger, R.A.; Tewari, K.S.; Backes, F.; Mannel, R.S.; Glaser, G.; Bailey, C.; Rubin, S.; Soper, J.; Lankes, H.A.; Ramirez, N.C.; King, M.C.; Birrer, M.J.; Swisher, E.M. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG oncology/gynecologic oncology group study. Clin. Cancer Res., 2018, 24(4), 777-783.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-1327] [PMID: 29191972]

Rights & Permissions Print Cite
Article Metrics
51
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy